Moreover, in RA patients, infliximab treatment led to sustained increases in paraoxonase and arylesterase activities of PON-1 on HDL-cholesterol molecules, which may improve HDL antiatherogenic capacity by increasing the antioxidative properties of HDL [37]. The gene discussed is PON1; the disease is rheumatoid arthritis.